Certified by Founder Lodge 
                                        
                                        Digitalis Ventures
 
                                                 United States  -  New York, NY 
                                             INVESTOR 
                                            
                                                                                    1 Disclosed Funding Rounds $100,000,000
                                            60 Participating Investments
- 
                                                Operating Status 
                                                
Active
 - 
                                                Last Funding Type 
                                                
Seed
 - 
                                                Company Type 
                                                
For Profit
 - Website
 - Contact
 - Social Links
 
                                            Digitalis Ventures is a venture capital firm that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, scientists, and inventors across
                                        
                                        
                                        
                                                                                
                                        
                                        
                                        
                                        
                                                                                
                                        | Company | Date | Round | Raised | 
|---|---|---|---|
   T-Therapeutics Ltd | 
                                                            November, 16 ,2023 | Series A | $59,707,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Ness | 
                                                            May, 11 ,2022 | Seed | $15,500,000 | 
   GRO Biosciences | 
                                                            July, 23 ,2024 | Series B | $60,300,000 | 
   Gallant Therapeutics | 
                                                            January, 09 ,2024 | Series A | $15,000,000 | 
   Matchpoint Therapeutics | 
                                                            October, 17 ,2022 | Series A | $100,000,000 | 
   Switch Therapeutics | 
                                                            March, 15 ,2023 | Series A | $52,000,000 | 
   Companion | 
                                                            April, 13 ,2023 | Unknown | $6,000,000 | 
   Ansel Health | 
                                                            January, 24 ,2024 | Unknown | $20,000,000 | 
   Eden Brew | 
                                                            May, 31 ,2022 | Unknown | $5,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Ascend Gene & Cell Therapies | 
                                                            May, 10 ,2023 | Series A | $132,500,000 | 
   MoeGo | 
                                                            March, 05 ,2024 | Series A | $24,000,000 | 
   Judo Bio | 
                                                            October, 08 ,2024 | Seed | $100,000,000 | 
   Companion | 
                                                            April, 13 ,2023 | Unknown | $6,000,000 | 
   T-Therapeutics Ltd | 
                                                            November, 16 ,2023 | Series A | $59,707,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Ness | 
                                                            May, 11 ,2022 | Seed | $15,500,000 | 
   Gallant Therapeutics | 
                                                            January, 09 ,2024 | Series A | $15,000,000 | 
   Ascend Gene & Cell Therapies | 
                                                            May, 10 ,2023 | Series A | $132,500,000 | 
   Switch Therapeutics | 
                                                            March, 15 ,2023 | Series A | $52,000,000 | 
   ELEGEN | 
                                                            May, 16 ,2024 | Series B | $35,000,000 | 
   Ansel Health | 
                                                            January, 24 ,2024 | Unknown | $20,000,000 | 
   T-Therapeutics Ltd | 
                                                            November, 16 ,2023 | Series A | $59,707,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Gallant Therapeutics | 
                                                            January, 09 ,2024 | Series A | $15,000,000 | 
   MoeGo | 
                                                            March, 05 ,2024 | Series A | $24,000,000 | 
   GRO Biosciences | 
                                                            July, 23 ,2024 | Series B | $60,300,000 | 
   Companion | 
                                                            April, 13 ,2023 | Unknown | $6,000,000 | 
   Ansel Health | 
                                                            January, 24 ,2024 | Unknown | $20,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Judo Bio | 
                                                            October, 08 ,2024 | Seed | $100,000,000 | 
   Ascend Gene & Cell Therapies | 
                                                            May, 10 ,2023 | Series A | $132,500,000 | 
   MoeGo | 
                                                            March, 05 ,2024 | Series A | $24,000,000 | 
   ELEGEN | 
                                                            May, 16 ,2024 | Series B | $35,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   T-Therapeutics Ltd | 
                                                            November, 16 ,2023 | Series A | $59,707,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Gallant Therapeutics | 
                                                            January, 09 ,2024 | Series A | $15,000,000 | 
   Galatea Bio Inc. | 
                                                            March, 28 ,2025 | Unknown | $25,000,000 | 
   GRO Biosciences | 
                                                            July, 23 ,2024 | Series B | $60,300,000 | 
   ELEGEN | 
                                                            May, 16 ,2024 | Series B | $35,000,000 | 
   Ansel Health | 
                                                            January, 24 ,2024 | Unknown | $20,000,000 | 
   GRO Biosciences | 
                                                            July, 23 ,2024 | Series B | $60,300,000 | 
   Judo Bio | 
                                                            October, 08 ,2024 | Seed | $100,000,000 | 
   Judo Bio | 
                                                            October, 08 ,2024 | Seed | $100,000,000 | 
   MoeGo | 
                                                            March, 05 ,2024 | Series A | $24,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Galatea Bio Inc. | 
                                                            March, 28 ,2025 | Unknown | $25,000,000 | 
   Alterome Therapeutics, Inc | 
                                                            April, 09 ,2024 | Series B | $132,000,000 | 
   Positive Development | 
                                                            August, 07 ,2025 | Unknown | $51,500,000 | 
   Galatea Bio Inc. | 
                                                            March, 28 ,2025 | Unknown | $25,000,000 | 
   ELEGEN | 
                                                            May, 16 ,2024 | Series B | $35,000,000 | 
   GRO Biosciences | 
                                                            July, 23 ,2024 | Series B | $60,300,000 | 
   Judo Bio | 
                                                            October, 08 ,2024 | Seed | $100,000,000 | 
   Alpha-9 Oncology | 
                                                            October, 24 ,2024 | Series C | $175,000,000 | 
   Galatea Bio Inc. | 
                                                            March, 28 ,2025 | Unknown | $25,000,000 | 
   Positive Development | 
                                                            August, 07 ,2025 | Unknown | $51,500,000 | 
   Faeth Therapeutics | 
                                                            October, 21 ,2025 | Unknown | $25,000,000 | 
                                                
  T-Therapeutics Ltd
  Alpha-9 Oncology
  Ness
  GRO Biosciences
  Gallant Therapeutics
  Matchpoint Therapeutics
  Switch Therapeutics
  Companion
  Ansel Health
  Eden Brew
  Ascend Gene & Cell Therapies
  MoeGo
  Judo Bio
  Alterome Therapeutics, Inc
  ELEGEN
  Galatea Bio Inc.
  Positive Development
  Faeth Therapeutics
Cherry Ventures
 
                                            
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
                                                                        
                                Helex |  $3,500,000  | (Nov 4, 2025)
                                                                        
                                xMEMS |  $21,000,000  | (Nov 4, 2025)
                                                                        
                                catalyx space |  $5,400,000  | (Nov 4, 2025)
                                                                        
                                Cephia AI |  $4,000,000  | (Nov 4, 2025)
                                                                        
                                Ornn |  $5,700,000  | (Nov 4, 2025)